Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Clinical Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate Sterile Suspension
Authors not listed
University of Iowa · 2003
Abstract
The purpose of this study is to evaluate whether anecortave acetate can slow or stop the progression of age-related macular degeneration in patients who do not qualify for other studies and have no other treatment options.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Anonymous. (2003). Clinical Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate Sterile Suspension. <em>University of Iowa</em>. https://clinicaltrials.gov/study/NCT00349739
Vancouver
Anonymous. Clinical Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate Sterile Suspension. University of Iowa. 2003.
BibTeX
@misc{anon2003Clinic,
title = {Clinical Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate Sterile Suspension},
author = {Anonymous},
journal = {University of Iowa},
year = {2003},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Control Delivery Systems 2001
Open access · US-GOV
A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration
Nature reviews. Immunology 2013
Preprint · OA
Immunology of age-related macular degeneration
Alcon Research 2005
Open access · US-GOV
Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD)
Ophthalmology 2006
Citation only
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Alcon Research 2005
Open access · US-GOV
Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD)
Wills Eye 2012
Open access · US-GOV